Literature DB >> 8335348

An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality.

S E Bucklin1, R Silverstein, D C Morrison.   

Abstract

Lipopolysaccharide (LPS), a component of gram-negative bacterial outer cell walls, can stimulate lymphoreticular cells to produce cytokines such as tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), and IL-6. One of these proinflammatory cytokines, IL-6, induces hepatic synthesis of a class of proteins termed acute-phase proteins. D-Galactosamine inhibits acute-phase protein synthesis and concurrently sensitizes mice to a lethal dose of LPS approximately 10,000-fold. From these observations, we hypothesized that the acute-phase response may serve as a defense mechanism for protection of the host against the deleterious effects of LPS. To test this hypothesis, murine recombinant IL-6 (mrIL-6) was used to induce an acute-phase response prior to a lethal LPS challenge in both D-galactosamine-treated and normal mice. Induction of the acute-phase response by mrIL-6 was quantitated by measuring the concentrations of fibrinogen and complement component C3, two well-characterized acute-phase proteins, in the circulation. The effect of acute-phase and normal serum on TNF-alpha release by peritoneal macrophages stimulated with LPS in vitro was also examined. The results of these studies confirmed the induction of the acute-phase response by mrIL-6, as reflected in an approximate doubling in circulating levels of fibrinogen and C3. However, when either D-galactosamine-sensitized or normal mice were challenged with a lethal dose of LPS at various times after mrIL-6 administration, the acute-phase response induced by mrIL-6 did not alter either cumulative lethality or the kinetics of lethality. Additionally, compared with normal serum, acute-phase serum did not affect TNF-alpha release by peritoneal macrophages following LPS-mediated stimulation in vitro. Collectively, these studies would not support a dominant role for an IL-6-mediated acute-phase response as contributing to the resistance of normal mice compared with D-galactosamine-sensitized mice in LPS-induced lethal toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335348      PMCID: PMC280986          DOI: 10.1128/iai.61.8.3184-3189.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha.

Authors:  J M Alcorn; J Fierer; M Chojkier
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

3.  Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis.

Authors:  D O Keppler; J Pausch; K Decker
Journal:  J Biol Chem       Date:  1974-01-10       Impact factor: 5.157

4.  Structure and function of lipopolysaccharide binding protein.

Authors:  R R Schumann; S R Leong; G W Flaggs; P W Gray; S D Wright; J C Mathison; P S Tobias; R J Ulevitch
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

5.  Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein.

Authors:  D G Ritchie; G M Fuller
Journal:  Ann N Y Acad Sci       Date:  1983-06-27       Impact factor: 5.691

6.  Isolation and study of murine C3.

Authors:  M B Pepys; A C Dash; A H Fielder; D D Mirjah
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

7.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

8.  Galactosamine-induced sensitization to the lethal effects of endotoxin.

Authors:  C Galanos; M A Freudenberg; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

9.  Human tumor necrosis factor. Production, purification, and characterization.

Authors:  B B Aggarwal; W J Kohr; P E Hass; B Moffat; S A Spencer; W J Henzel; T S Bringman; G E Nedwin; D V Goeddel; R N Harkins
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

10.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Authors:  G Wakabayashi; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

View more
  5 in total

Review 1.  Cordelia, Goneril and the febrile response.

Authors:  P A Mackowiak
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

2.  Effect of transforming growth factor beta on experimental Salmonella typhimurium infection in mice.

Authors:  M Galdiero; A Marcatili; G Cipollaro de l'Ero; I Nuzzo; C Bentivoglio; M Galdiero; C Romano Carratelli
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

3.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

4.  Production of chemokines in Kawasaki disease, Henoch-Schönlein purpura and acute febrile illness.

Authors:  Hyo Seok Chung; Hyo Young Kim; Hee Sun Kim; Hee Jung Lee; Ji Hyun Yuh; Eun Sil Lee; Kwang Hae Choi; Young Hwan Lee
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

5.  Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease.

Authors:  G Mancuso; F Tomasello; M Migliardo; D Delfino; J Cochran; J A Cook; G Teti
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.